Article
Orthogonal proteomics methods warrants development of Duchenne Muscular Dystrophy biomarkers
2022-12-05
Abstract excerpt
<h4>Background: </h4> Molecular components in blood, like proteins, are used as biomarkers to reveal or predict disease states, guide clinical interventions and aid development of therapies. While multiplexing proteomics methods promote discovery of such biomarkers, it is generally difficult to translate them to clinical use due to lack of substantial evidence regarding their reliability as quantifiable indicators...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- fa57c46a-83e5-5c94-842b-35d94d47a710
- DOI
- 10.21203/rs.3.rs-2285032/v1